



## EOS imaging Announces System Installation at Shriners Hospital in Philadelphia

### *Fourth Installation in Renowned Shriners Hospitals for Children® System*

**Paris, Feb. 13, 2014** – EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in orthopaedic 2D/3D imaging, today announced the installation of the EOS imaging system at Shriners Hospitals for Children® in Philadelphia. This fourth installation within the Shriners Hospitals for Children system, a group of hospitals focused on caring for children with neuromusculoskeletal conditions and other specialty healthcare, validates the adoption of EOS technology as the standard of care for imaging within the network.

*“The EOS System offers unparalleled benefits in terms of reduced radiation dose, quicker scanning procedures and diagnostic content, and we are pleased to help make this technology more accessible to Shriners’ patients,”* said Amer Samdani, M.D., Chief of Surgery, Shriners Hospitals for Children-Philadelphia. *“EOS’ extremely low-dose system provides high quality 2D and 3D imaging that enables physicians to provide the care, attention and thoroughness necessary in the treatment of children with scoliosis or limb deformities. We are pleased to join the ranks of other Shriners Hospitals in Montreal, Portland (OR) and Greenville (SC), in utilizing this technology for our Philadelphia-area patients.”*

The Philadelphia Shriners Hospital treats more than 17,000 patients per year, with 68 percent of these patients treated for spinal conditions that require frequent imaging to track treatment progression. Scoliosis in particular requires regular screening over the course of many years of treatment, increasing exposure to harmful levels of radiation that may increase the likelihood of developing cancer in later years.

The EOS system provides full-body images of patients in a natural standing or seated position in both 2D and 3D. The system also delivers a radiation dose that has been measured to be nine times lower than that of computed radiography X-ray<sup>1</sup> and 20 times lower than basic CT scans<sup>2</sup> in accordance with the ALARA (As Low As Reasonably Achievable) principle of radiation reduction. For these reasons, the EOS system is the ideal mode of imaging for monitoring the treatment of pediatric scoliosis patients like those who seek treatment at Shriners Hospitals.

Marie Meynadier, CEO of EOS imaging, said, *“We are proud to strengthen our relationship with the Shriners Hospital system and progressively become a standard of care in pediatric orthopaedic imaging within this organization. The successful addition of Philadelphia to the other Shriners Hospitals using the EOS system speaks to the continued utility of our offering for safe and efficient treatment planning and monitoring. We’re excited to work with the Shriners Hospitals for Children organization by providing a comprehensive 2D/3D imaging modality that supports the outstanding work they do in pediatric orthopaedic care.”*

For more information, please visit [www.eos-imaging.com](http://www.eos-imaging.com).

<sup>1</sup> S. Parent et al. Diagnostic imaging of spinal deformities: Reducing patients radiation dose with a new slot-scanning x-ray imager. *Spine*. April 2010

<sup>2</sup> D. Folinais et al. Lower Limb Torsional assessment: comparison EOS/CT Scan. *JFR* 2011.



**About Shriners Hospitals for Children:**

Shriners Hospitals for Children is changing lives every day through innovative pediatric specialty care, world-class research and outstanding medical education. Our 22 facilities, located in the United States, Canada and Mexico, provide advanced care for children with orthopaedic conditions, burns, spinal cord injuries, and cleft lip and palate. Learn more at [www.shrinershospitalsforchildren.org](http://www.shrinershospitalsforchildren.org).

**About EOS imaging:**

EOS imaging designs, develops, and markets EOS<sup>®</sup>, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 31 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 75 sites and more than 400,000 imaging sessions, EOS<sup>®</sup> benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 102 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore. For further information, please visit [www.eos-imaging.com](http://www.eos-imaging.com)

EOS imaging is listed on Compartment C of the NYSE Euronext Paris  
ISIN: FR0011191766 – Ticker: EOSI

Next press release: 2013 annual results on April 8, 2014 (after market).



**Contacts:**

**Anne Renevot  
CFO**

Tel.: +33 (0)1 55 25 61 24  
[investors@eos-imaging.com](mailto:investors@eos-imaging.com)

**NewCap**

Financial communication and investor relations  
Sophie Boulila / Pierre Laurent  
Tel.: +33 (0)1 44 71 94 91 - [eosimaging@newcap.fr](mailto:eosimaging@newcap.fr)

**The Ruth Group (US)**

Press relations  
Melanie Sollid-Penton  
Ph: 646-536-7023  
[msollid@theruthgroup.com](mailto:msollid@theruthgroup.com)